Serum levels of growth factors in patients with urinary bladder cancer

2017 ◽  
Vol 42 (5) ◽  
Author(s):  
Şölen Himmetoğlu ◽  
Mustafa Bilal Tuna ◽  
Eylem Efe Koç ◽  
Süleyman Ataus ◽  
Yildiz Dincer
Keyword(s):  
Bladder Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Serum Level ◽  
Urinary Bladder ◽  
Urinary Bladder Cancer ◽  
Serum Levels ◽  
Control Group ◽  
Her 2 ◽  
Epidermal Growth

AbstractBackground:Altered signalling of human epidermal growth factor receptor-2 (HER-2/neu), insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) have been shown to play important role in tumor development and progression in various cancers. Their serum levels may be reliable indicator for diagnosis and progression of cancer.Objective:To examine the serum levels of soluble HER-2/neu (sHER-2/neu), IGF1 and EGF in patients with urinary bladder cancer (UBC).Material and methods:Serum levels of sHER-2/neu, IGF1 and EGF were measured by enzyme-linked immune assay in newly diagnosed, untreated patients with UBC.Results:In the patient group, sHER-2/neu level was found to be increased, IGF1 level was found to be decreased in comparison to those in the control group. Although serum level of sHER-2/neu was lower in the patients with Ta stage than that in the patients with T1 and T2 stages, this difference was not at a statistically significant level.Conclusion:Serum level of sHER-2/neu is increased in patients with UBC. Despite the lack of a significant association between sHER-2/neu level and pathological pT stage, sHER-2/neu may be a promising marker for UBC but IGF-1 and EGF have not such a potential.

Serum Levels of Epidermal Growth Factor, Transforming Growth Factor, and c-erbB2 in Ovarian Cancer

2012 ◽  
Vol 22 (7) ◽  
pp. 1138-1142 ◽  
Author(s):  
Eray Balcan ◽  
Fuat Demirkiran ◽  
Yavuz Aydin ◽  
Cevdet Sanioglu ◽  
Tugan Bese ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Control Group ◽  
Study Group ◽  
Cutoff Value ◽  
Histological Types ◽  
Epidermal Growth

ObjectiveThis study aimed to investigate serum levels of epidermal growth factor (EGF), transforming growth factor α (TGF-α), and c-erbB2 in patients with ovarian cancer.Materials and MethodsIn this retrospective cohort study, the study and control groups were composed of 43 women with a prediagnosis of ovarian cancer and 43 healthy women, respectively. Blood samples from all women were obtained and studied by enzyme-linked immunosorbent assay kits for EGF, TGF-α, and c-erbB2. After surgery of the study group, ovarian cancer was confirmed and compared with control group. Stage, grade, and histological types were defined after histopathologic examination, and subgroups were constructed and compared.ResultsSerum EGF, TGF-α, and c-erbB2 levels were significantly increased in study group compared with those in the control group (P < 0.001). There were no differences in serum levels of EGF, TGF-α, and c-erbB2 among all stages, grades, and histological types of ovarian cancer. If 47.90 pg/mL was selected as the cutoff value, EGF has an 80% sensitivity and a 65% specificity for detecting ovarian cancer. The cutoff value of 41,095.00 pg/mL for TGF-α has a 90% sensitivity and a 72% specificity for detecting ovarian cancer. The c-erbB2 level of 4.63 pg/mL as the cutoff value has an 83% sensitivity and a 76% specificity for predicting ovarian cancer.ConclusionsSerum levels of EGF, TGF-α, and c-erbB2 may be used for diagnosing ovarian cancer.

scholarly journals Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders—Longitudinal Study in Adolescent and Young Adult Patients

2021 ◽  
Vol 10 (18) ◽  
pp. 4064
Author(s):  
Maria Skibinska ◽  
Pawel Kapelski ◽  
Monika Dmitrzak-Weglarz ◽  
Natalia Lepczynska ◽  
Joanna Pawlak ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Mood Disorders ◽  
Young Patients ◽  
Serum Levels ◽  
Adolescent And Young Adult ◽  
Control Group ◽  
Replication Studies ◽  
Epidermal Growth

Bipolar disorder (BD) is a chronic mental disorder that affects more than 1% of the population worldwide. Over 65% of patients experience early onset of the disease. Most cases of juvenile bipolar disorder begin with a depressed mood episode, and up to 50% of youth initially diagnosed with major depression go onto developing a BD. Our study aimed to find biomarkers of diagnosis conversion in young patients with mood disorders. We performed a two-year follow-up study on 79 adolescent patients diagnosed with MDD or BD, with a detailed clinical assessment at five visits. We monitored diagnosis change from MDD to BD. The control group consisted of 31 healthy youths. According to the neurodevelopmental and neuroimmunological hypotheses of mood disorders, we analyzed serum levels of brain-derived neurotrophic factor (BDNF), proBDNF, epidermal growth factor (EGF), migration inhibitory factor (MIF), stem cell factor (SCF), and correlations with clinical factors. We detected a significant disease-dependent increase in EGF level in MDD and BP patients at baseline exacerbation of depressive or hypomanic/manic episodes as well as in euthymic state compared to healthy controls. No potential biological predictors of disease conversion were found. Replication studies on a larger cohort of patients are needed.

947: Chemopreventive Effects of COX-2 Inhibitor and Epidermal Growth Factor (EGF)-Receptor Kinase Inhibitor on Rat Urinary Bladder Tumorigenesis

2004 ◽  
Vol 171 (4S) ◽  
pp. 251-251
Author(s):  
Kazunori Hattori ◽  
Katsuyuki Iida ◽  
Akira Johraku ◽  
Sadamu Tsukamoto ◽  
Taeko Asano ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Urinary Bladder ◽  
Egf Receptor ◽  
Kinase Inhibitor ◽  
Receptor Kinase ◽  
Rat Urinary Bladder ◽  
Epidermal Growth ◽  
Cox 2
Sign in / Sign up

Export Citation Format

Share Document